Summitry LLC Invests $124,000 in Certara, Inc. (NASDAQ:CERT)

Summitry LLC purchased a new position in Certara, Inc. (NASDAQ:CERT) during the fourth quarter, Holdings Channel reports. The firm purchased 11,653 shares of the company’s stock, valued at approximately $124,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Venturi Wealth Management LLC increased its holdings in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after buying an additional 2,509 shares during the period. Blue Trust Inc. boosted its position in shares of Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after acquiring an additional 3,656 shares during the last quarter. KBC Group NV raised its position in Certara by 64.1% during the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after purchasing an additional 3,125 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of CERT stock opened at $10.32 on Wednesday. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -51.60, a PEG ratio of 9.29 and a beta of 1.60. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average price is $12.54 and its 200-day moving average price is $11.47. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.18.

Analyst Ratings Changes

CERT has been the topic of several recent analyst reports. Stephens reiterated an “overweight” rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. William Blair reaffirmed a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 target price for the company. Finally, Barclays raised their price target on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.83.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.